LA
Insider buying
Lawrence A Kenyon bought Outlook Therapeutics, Inc. (OTLK) stock
Lawrence A Kenyon, Chief Financial Officer of Outlook Therapeutics, Inc. (OTLK), bought 101,010 shares of OTLK stock, per an SEC Form 4 filed Aug 14, 2026.
The shares came through a private deal, not the open market.
The trade was reported on Aug 14, 2026.
OTLK has moved -22.6% since the trade date, from $0.76 to $0.59 (Oct 12, 2026 close).
- Traded
- Aug 14, 2026
- Disclosed
- Aug 14, 2026
- Filing delay
- 0 days
- Price since
- -22.6%
- Role
- Chief Financial Officer
- Source
- SEC Form 4
More OTLK insider and Congress trades
From a public SEC Form 4, linked above. Not investment advice, and not a recommendation to buy or sell.